Autopsy report · NCT00384605

An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)

“The overall profile does not support development for obesity”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 2 months before it stopped.
• 1,000 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Obesity

Interventions

taranabant; placebo

Participants

1,000

Trials that died the same way

• PregnanT Moms Measure - Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women
  “Not enough obese subjects could be recruited.” (59% match in meaning)
• Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity
  “Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.